DexCom, Inc. (NASDAQ:DXCM) – Analysts at William Blair lifted their Q4 2017 EPS estimates for DexCom in a note issued to investors on Tuesday. William Blair analyst M. Kaczor now anticipates that the medical device company will earn $0.06 per share for the quarter, up from their prior estimate of $0.02. William Blair also issued estimates for DexCom’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.08) EPS and FY2018 earnings at ($0.56) EPS.
DXCM has been the subject of a number of other reports. BMO Capital Markets reissued an “outperform” rating and issued a $62.00 price objective (down from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Raymond James Financial cut shares of DexCom from an “outperform” rating to a “mkt perform” rating in a research note on Friday, September 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $69.00 price target (down from $90.00) on shares of DexCom in a research note on Thursday, September 28th. TheStreet cut shares of DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. Finally, Stephens reaffirmed a “buy” rating and set a $70.00 price target (down from $83.00) on shares of DexCom in a research note on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. DexCom presently has an average rating of “Buy” and an average price target of $72.31.
In related news, EVP Andrew K. Balo sold 6,490 shares of DexCom stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $60.00, for a total transaction of $389,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $44.82, for a total transaction of $73,280.70. Following the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold a total of 38,140 shares of company stock valued at $2,158,576 in the last quarter. 1.70% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Winslow Capital Management LLC bought a new stake in DexCom during the 2nd quarter valued at about $117,451,000. State Street Corp lifted its holdings in DexCom by 2.5% during the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after buying an additional 37,581 shares in the last quarter. Peregrine Capital Management LLC raised its holdings in shares of DexCom by 24.5% in the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock valued at $19,348,000 after purchasing an additional 77,868 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of DexCom by 3.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock valued at $12,967,000 after purchasing an additional 8,171 shares in the last quarter. Finally, Macquarie Group Ltd. raised its holdings in shares of DexCom by 67.2% in the 2nd quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock valued at $17,746,000 after purchasing an additional 97,479 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: “Q4 2017 EPS Estimates for DexCom, Inc. Lifted by William Blair (DXCM)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.com-unik.info/2018/01/12/q4-2017-eps-estimates-for-dexcom-inc-lifted-by-william-blair-dxcm.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
What are top analysts saying about DexCom? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom and related companies.